In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

Processa Pharmaceuticals has dosed the first subject in its Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) to treat patients with advanced or metastatic breast cancer.

Background. A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin.

Earlier this year, physician Edward Greeno discovered that one of his patients had missed a dose of capecitabine, the oral chemotherapy drug he had prescribed to treat her colorectal cancer. But he ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.

In view of the patient's long progression-free survival (12.9 months), we decided to resume intramuscular octreotide (30 mg every 3 weeks) with capecitabine and liposomal doxorubicin chemotherapy ...

During the first cycle of capecitabine development, three concomitant drugs were found to affect 5-FU clearance. [5] Paracetamol and morphine increased 5-FU clearance by 26% and 41%, respectively ...